[December 15, 2017] |
|
U.S. Durezol Promotional Report 2016-2017 - Research and Markets
The "Durezol
2016 U.S. Promotional Report" report has been added to Research
and Markets' offering.
The 5 Key Questions Addressed by this Report:
-
How many physicians were reached by Durezol through personal promotion
in 2016 and how does this compare to its peer set in the Ocular
Inflammation, Ocular Pain, and Uveitis markets?
-
What promotional mix was leveraged (e.g., sales rep detailing,
physician education, and paid speaking) and what was the median spend
on each type of activity?
-
How does Alcon Labs's depth of coverage vary within key specialties
(e.g., Ophthalmology and Optometry) and how does this compare to its
peers and the overall set of rep-accessible hysicians?
-
How often are physicians receiving paid meals for Durezol throughout
the year (e.g., monthly, quarterly, annually)?
-
Who were the most detailed prescribers and top paid speakers for
Durezol in 2016?
Data Sources and Methodology:
-
We leverage company-reported financial transaction data disclosed
through CMS Open Payments. This data set captures all transfers of
value (e.g., speaking fees, consulting fees, travel, education, and
meals) made on behalf of a drug or device manufacturer to a physician.
Currently, 42 months of longitudinal data is available - covering
payments to more than 900,000 U.S. healthcare professionals.
-
Over 5,200 paid interactions across 3,200 physicians made on behalf of
Durezol were carefully examined to support our analysis. In addition,
interaction data from 11 peer products (e.g. Alrex, Avenova, Bromsite,
Ilevro, Lotemax, Ozurdex, Prolensa, Restasis, Systane, Xiidra, and
Zylet) was leveraged to provide benchmarking and market insights.
For more information about this report visit https://www.researchandmarkets.com/research/n4lj3f/u_sdurezol?w=4
View source version on businesswire.com: http://www.businesswire.com/news/home/20171215005492/en/
[ Back To TMCnet.com's Homepage ]
|